Ipsen

Paris, France | August 21, 2026 Ipsen announced the completion of its acquisition of Kartos Therapeutics, strengthening its late-stage...

PARIS, France, July 24, 2026 Ipsen announced that its Phase III BOLD clinical trial evaluating Bylvay® (odevixibat) in patients...

PARIS, France, July 9, 2026 Ipsen has announced positive topline Phase III results from its BEOND clinical development program,...

PARIS, France & SCHLIEREN/ZURICH, Switzerland, July 1, 2026 Ipsen has announced a definitive agreement to acquire Memo Therapeutics AG,...

PARIS, France & REDWOOD CITY, Calif., June 29, 2026 Ipsen has announced a definitive agreement to acquire Kartos Therapeutics,...

Paris, France – April 22, 2026 In a major breakthrough for pediatric oncology, Ipsen has announced that the European...

Paris, France, December 19, 2025 — Ipsen, a global biopharmaceutical company, announced an update on its pivotal Phase II...